BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9820586)

  • 1. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
    Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
    Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
    Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
    Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
    Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
    Beck FW; Al-Katib AM; Ahmad I; Wall NR; Liu KZ; Mantsch HH; Mohammad RM
    Int J Mol Med; 2000 Apr; 5(4):341-7. PubMed ID: 10719048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.
    Beck FW; Eilender DS; Dandashi MH; Siddiq F; Snell DC; Godmere MA; Al-Katib AM; Mohammad RM
    Int J Mol Med; 2004 Jul; 14(1):113-9. PubMed ID: 15202025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
    Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.
    Wall NR; Beck FW; Al-Katib AM; Mohammad RM
    J Drug Target; 2001; 9(5):329-39. PubMed ID: 11770703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study.
    Liu KZ; Schultz CP; Mohammad RM; Al-Katib AM; Johnston JB; Mantsch HH
    Cancer Lett; 1998 May; 127(1-2):185-93. PubMed ID: 9619876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.
    Kawasaki H; Carrera CJ; Piro LD; Saven A; Kipps TJ; Carson DA
    Blood; 1993 Feb; 81(3):597-601. PubMed ID: 8094016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
    Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
    Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
    Wang H; Mohammad RM; Werdell J; Shekhar PV
    Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
    Thomas A; Pepper C; Hoy T; Bentley P
    Leuk Lymphoma; 2004 May; 45(5):997-1008. PubMed ID: 15291360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
    Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
    Kitada S; Zapata JM; Andreeff M; Reed JC
    Br J Haematol; 1999 Sep; 106(4):995-1004. PubMed ID: 10520003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line.
    Liu KZ; Schultz CP; Johnston JB; Beck FW; Al-Katib AM; Mohammad RM; Mantsch HH
    Leukemia; 1999 Aug; 13(8):1273-80. PubMed ID: 10450757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.
    Wall NR; Mohammad RM; Al-Katib AM
    Leuk Res; 1999 Oct; 23(10):881-8. PubMed ID: 10573132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
    Petersen AJ; Brown RD; Gibson J; Pope B; Luo XF; Schutz L; Wiley JS; Joshua DE
    Eur J Haematol; 1996 Apr; 56(4):213-20. PubMed ID: 8641389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.
    Maki A; Diwakaran H; Redman B; al-Asfar S; Pettit GR; Mohammad RM; al-Katib A
    Anticancer Drugs; 1995 Jun; 6(3):392-7. PubMed ID: 7670136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
    Mohammad RM; Diwakaran H; Maki A; Emara MA; Pettit GR; Redman B; al-Katib A
    Leuk Res; 1995 Sep; 19(9):667-73. PubMed ID: 7564478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.